Aardvark Therapeutics, Inc.

AARD

Explore Our Financial Data > Companies > Aardvark Therapeutics, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	AARD
CIK	0001774857
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	4370 LA JOLLA VILLAGE DRIVE, SUITE 1050, SAN DIEGO, CA, 92122
Website	aardvarktherapeutics.com
Phone	(858) 225-7696
CEO	Tien-Li Lee
Employees	18

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	N/A
Pre-Tax Income	N/A
Net Income	N/A
Net Income to Common	N/A
EPS	N/A

View All

Balance Sheet

Cash	$26.00 million
Assets	$147.48 million
Liabilities	$10.55 million
Common Equity	$136.92 million
Liabilities & Equity	$147.48 million

View All

Cash Flow Statement

Net Income	N/A
Cash From Operating Activities	N/A
Cash From Investing Activities	N/A
Cash From Financing Activities	N/A
Change in Cash	N/A

View All

Calculations

NOPAT	$0.00
EBITDA	$0.00
Price to Earnings	N/A
Price to Book	$1.36
ROE	0.00%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today announced that on August 28, 2025, two new employees were granted inducement awards consisting of stock options to purchase an aggregate of 20,013 shares of common stock. Each option was granted pursuant to the Aardvark Therapeutics, Inc. 2025 Induceme

Article Link

2 ‘Strong Buy’ Growth Stocks Offering 300% or Higher Upside

With an interesting and innovative pipeline, these two small-cap biotechs have the potential to soar high.

Article Link

Aardvark Therapeutics to Present at Upcoming Investor Conferences in September

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during September: Cantor Fitzgerald Global Healthcare Conference 2025 in New YorkPresentation: Wednesday, September 3 at 11:30 a.m. ET Morgan Stanley 23rd Annu

Article Link

Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients discontinuing GLP-1RA therapy, while Phase 2 STRENGTH trial to focus on durable weight loss as a monotherapy and in combination with GLP-1RA.Anticipated expansion of Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS) to include pediatric population you

Article Link

Retail investors among Aardvark Therapeutics, Inc.'s (NASDAQ:AARD) largest stockholders and were hit after last week's 11% price drop

NasdaqGS:AARD 1 Year Share Price vs Fair Value Explore Aardvark Therapeutics's Fair Values from the Community and...

Article Link